DEFINE - a Randomized, Open-Label Trial of the Inhaled Galectin-3 Inhibitor GB0139 in Hospitalized Patients with Moderate-to-Severe COVID-19

被引:0
|
作者
Gaughan, E. [1 ]
Sethi, T. [2 ]
Quinn, T. [1 ]
Hirnani, N. [1 ]
Mills, A. [3 ]
Bruce, A. M. [1 ]
Mackinnon, A. [2 ]
Aslanis, V. [2 ]
Li, F. [1 ]
O'Connor, R. [1 ]
Dear, J. [4 ]
Akram, A. R. [1 ]
Koch, O. [5 ]
Wang-Jairaj, J. [2 ]
Slack, R. J. [2 ]
Gravelle, L. [2 ]
Lindmark, B. [2 ]
Dhaliwal, K. [1 ]
机构
[1] Univ Edinburgh, Ctr Inflammat Res, Edinburgh, Midlothian, Scotland
[2] Galecto Inc, Copenhagen, Denmark
[3] Explorist, Belfast, Antrim, North Ireland
[4] Univ Edinburgh, Ctr Cardiovasc Sci, Edinburgh, Midlothian, Scotland
[5] NHS Lothian, Infect Dis Dept, Edinburgh, Midlothian, Scotland
关键词
D O I
暂无
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
A3127
引用
收藏
页数:2
相关论文
共 50 条
  • [1] An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE)
    Gaughan, Erin E.
    Quinn, Tom M.
    Mills, Andrew
    Bruce, Annya M.
    Antonelli, Jean
    MacKinnon, Alison C.
    Aslanis, Vassilios
    Li, Feng
    O'Connor, Richard
    Boz, Cecilia
    Mills, Ross
    Emanuel, Philip
    Burgess, Matthew
    Rinaldi, Giulia
    Valanciute, Asta
    Mills, Bethany
    Scholefield, Emma
    Hardisty, Gareth
    Findlay, Emily Gwyer
    Parker, Richard A.
    Norrie, John
    Dear, James W.
    Akram, Ahsan R.
    Koch, Oliver
    Templeton, Kate
    Dockrell, David H.
    Walsh, Timothy S.
    Partridge, Stephen
    Humphries, Duncan
    Wang-Jairaj, Jie
    Slack, Robert J.
    Schambye, Hans
    Phung, De
    Gravelle, Lise
    Lindmark, Bertil
    Shankar-Hari, Manu
    Hirani, Nikhil
    Sethi, Tariq
    Dhaliwal, Kevin
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207 (02) : 138 - 149
  • [2] Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial
    Wang, Dongsheng
    Fu, Binqing
    Peng, Zhen
    Yang, Dongliang
    Han, Mingfeng
    Li, Min
    Yang, Yun
    Yang, Tianjun
    Sun, Liangye
    Li, Wei
    Shi, Wei
    Yao, Xin
    Ma, Yan
    Xu, Fei
    Wang, Xiaojing
    Chen, Jun
    Xia, Daqing
    Sun, Yubei
    Dong, Lin
    Wang, Jumei
    Zhu, Xiaoyu
    Zhang, Min
    Zhou, Yonggang
    Pan, Aijun
    Hu, Xiaowen
    Mei, Xiaodong
    Wei, Haiming
    Xu, Xiaoling
    FRONTIERS OF MEDICINE, 2021, 15 (03) : 486 - 494
  • [3] Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial
    Dongsheng Wang
    Binqing Fu
    Zhen Peng
    Dongliang Yang
    Mingfeng Han
    Min Li
    Yun Yang
    Tianjun Yang
    Liangye Sun
    Wei Li
    Wei Shi
    Xin Yao
    Yan Ma
    Fei Xu
    Xiaojing Wang
    Jun Chen
    Daqing Xia
    Yubei Sun
    Lin Dong
    Jumei Wang
    Xiaoyu Zhu
    Min Zhang
    Yonggang Zhou
    Aijun Pan
    Xiaowen Hu
    Xiaodong Mei
    Haiming Wei
    Xiaoling Xu
    Frontiers of Medicine, 2021, 15 : 486 - 494
  • [4] Tocilizumab in patients with moderate or severe COVID-19:a randomized, controlled, open-label, multicenter trial
    Dongsheng Wang
    Binqing Fu
    Zhen Peng
    Dongliang Yang
    Mingfeng Han
    Min Li
    Yun Yang
    Tianjun Yang
    Liangye Sun
    Wei Li
    Wei Shi
    Xin Yao
    Yan Ma
    Fei Xu
    Xiaojing Wang
    Jun Chen
    Daqing Xia
    Yubei Sun
    Lin Dong
    Jumei Wang
    Xiaoyu Zhu
    Min Zhang
    Yonggang Zhou
    Aijun Pan
    Xiaowen Hu
    Xiaodong Mei
    Haiming Wei
    Xiaoling Xu
    Frontiers of Medicine, 2021, 15 (03) : 486 - 494
  • [5] severe COVID-19 Patients: A Multicenter, Randomized, Open-Label Clinical Trial
    Trinh, Dieu-Thuong Thi
    Tran, An Hoa
    Bui, Minh-Man Pham
    Kieu, Thy Xuan
    Nguyen, Van -Dan
    Thuy, Nguyen Huu Lac
    Thai, Khac-Minh
    Vuong, Nguyen Lam
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (06)
  • [6] Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial
    Philippe Bégin
    Jeannie Callum
    Erin Jamula
    Richard Cook
    Nancy M. Heddle
    Alan Tinmouth
    Michelle P. Zeller
    Guillaume Beaudoin-Bussières
    Luiz Amorim
    Renée Bazin
    Kent Cadogan Loftsgard
    Richard Carl
    Michaël Chassé
    Melissa M. Cushing
    Nick Daneman
    Dana V. Devine
    Jeannot Dumaresq
    Dean A. Fergusson
    Caroline Gabe
    Marshall J. Glesby
    Na Li
    Yang Liu
    Allison McGeer
    Nancy Robitaille
    Bruce S. Sachais
    Damon C. Scales
    Lisa Schwartz
    Nadine Shehata
    Alexis F. Turgeon
    Heidi Wood
    Ryan Zarychanski
    Andrés Finzi
    Donald M. Arnold
    Nature Medicine, 2021, 27 : 2012 - 2024
  • [7] Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial
    Begin, Philippe
    Callum, Jeannie
    Jamula, Erin
    Cook, Richard
    Heddle, Nancy M.
    Tinmouth, Alan
    Zeller, Michelle P.
    Beaudoin-Bussieres, Guillaume
    Amorim, Luiz
    Bazin, Renee
    Loftsgard, Kent Cadogan
    Carl, Richard
    Chasse, Michael
    Cushing, Melissa M.
    Daneman, Nick
    Devine, Dana, V
    Dumaresq, Jeannot
    Fergusson, Dean A.
    Gabe, Caroline
    Glesby, Marshall J.
    Li, Na
    Liu, Yang
    McGeer, Allison
    Robitaille, Nancy
    Sachais, Bruce S.
    Scales, Damon C.
    Schwartz, Lisa
    Shehata, Nadine
    Turgeon, Alexis F.
    Wood, Heidi
    Zarychanski, Ryan
    Finzi, Andres
    Arnold, Donald M.
    NATURE MEDICINE, 2021, 27 (11) : 2012 - +
  • [8] Subcutaneous IL-6 Inhibitor Sarilumab vs. Standard Care in Hospitalized Patients With Moderate-To-Severe COVID-19: An Open Label Randomized Clinical Trial
    Garcia-Vicuna, Rosario
    Rodriguez-Garcia, Sebastian C.
    Abad-Santos, Francisco
    Hernandez, Azucena Bautista
    Garcia-Fraile, Lucio
    Blandino, Ana Barrios
    Liarte, Angela Gutierrez
    Alonso-Perez, Tamara
    Cardenoso, Laura
    Alfranca, Aranzazu
    Mejia-Abril, Gina
    Sanz, Jesus Sanz
    Gonzalez-Alvaro, Isidoro
    FRONTIERS IN MEDICINE, 2022, 9
  • [9] Adding colchicine to tocilizumab in hospitalized patients with severe COVID-19 pneumonia: An open-label randomized controlled trial
    Rahhal, Alaa
    Najim, Mostafa
    Aljundi, Amer Hussein
    Mahfouz, Ahmed
    Alyafei, Sumaya Mehdar
    Awaisu, Ahmed
    Habib, Mhd Baraa
    Obeidat, Ibrahim
    Faisal, Mohanad Mohammed
    Alanzi, Meshaal Ali
    Nair, Arun Prabhakaran
    Elhassan, Areeg
    Al-Dushain, Abdullah
    Abdelmajid, Alaaeldin Abdelmajid
    Abdelgader, Ahmed Elfadil
    Moursi, Ahmed Mahmoud Ahmed
    Alharafsheh, Ahmad Eid Nazzal
    Abou Kamar, Mohd Ragheb
    Goravey, Wael
    Omar, Amr Salah
    Abukhattab, Mohammed
    Khatib, Mohamad Yahya
    Mohamedali, Mohamed Gaafar
    AlMaslamani, Muna A. Rahman
    Alemadi, Samar
    MEDICINE, 2022, 101 (39) : E30618
  • [10] COVID-19: Inhaled galectin-3 inhibitor safe and effective?
    Simon, Annika
    PNEUMOLOGIE, 2023, 77 (09):